ESH 2017 | CAR T-cells and CRISPR: The future of AML treatment
Saar Gill
• 5 Oct 2017
New and invigorating methods of tackling acute myeloid leukemia (AML) are being researched at present. In this interview, Saar Gill, MD, PhD from the University of Pennsylvania, Philadelphia, PA talks about his research into AML, which focuses on CD33 and CD123 using CAR T-cell therapy. Dr Gill discusses the current issues with this therapy and provides an overview of how his group is planning to overcome these problem by utilising CRISPR-Cas9. This interview was recorded at the International Conference of Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).
